Additionally, we stated in the CY 2026 OPPS/ASC proposed rule that we believe that the pass-through payment category C1765 may also appropriately describe the Axoguard HA+ Nerve Protector TM because the device, as described by the applicant, is designed to be placed on and around neural structures to be a protective interface between a nerve and the surrounding tissue, to minimize the potential for soft tissue attachments, and to ensure the nerve's ability to glide through tissue structures during anatomic movement, and therefore may be appropriately described as an adhesion barrier consistent with devices described by C1765
2006 (Achilles detachment in rat, J Orthop Res) and Chang et al
Patients come in having used a telehealth peptide platform for 23 months with inconsistent results
Always work with a licensed medical provider, never with unregulated online vendors
We do not create new APCs with a comprehensive geometric mean cost that is higher than the highest geometric mean cost (or only) C-APC in a clinical family just to accommodate potential complexity adjustments
The right choice depends on your compound's isoelectric point (pI)
.png)
